Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 1 2Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

PIK3CA-Mutated Cancers 1Colorectal Neoplasms 1

Interventions

Specimen Handling 98Biopsy 69Magnetic Resonance Spectroscopy 63pembrolizumab 46Cyclophosphamide 43fludarabine 38Carboplatin 22venetoclax 19Nivolumab 18Cetuximab 18Bevacizumab 17Radiotherapy 16fludarabine phosphate 15Cisplatin 15X-Rays 14Ipilimumab 13Fluorouracil 13Cytarabine 13Temozolomide 12Leucovorin 12Irinotecan 12atezolizumab 11Radiation 11Paclitaxel 11Azacitidine 11durvalumab 10Oxaliplatin 10Injections 10Gemcitabine 10Dexamethasone 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × inavolisib × 30 days × Clear all
NCT06496568 2026-05-27

A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

Hoffmann-La Roche

Phase 1 Active not recruiting
30 enrolled

PIK3CA-Mutated Cancers

NCT04929223 2026-05-26

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Hoffmann-La Roche

Phase 1 Recruiting
542 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡